NCT03207347 2023-09-15A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)University of FloridaPhase 2 Completed37 enrolled 15 charts
NCT02315066 2022-04-21Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566PfizerPhase 1 Completed174 enrolled 68 charts